Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in L'aquila

33 clinical trials in L'aquila, Italy. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
L'aquila at a glance
33
clinical trials
  • Not yet recruiting0
  • Research sites0
Type of trial
Recruitment status
Quick filters

33 trials in L'aquila

Open in trial search

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Cardiovascular disorder+2

Recruiting

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hormone-refractory prostate cancer

Recruiting

Study Comparing Docetaxel and Androgen Receptor-Targeted Agents (Abiraterone or Enzalutamide) for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Recruiting
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Cerebrovascular accident

Recruiting

Study on Tranexamic Acid and Sodium Chloride for Patients with Stroke-Related Brain Bleeding

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:University Of Nottingham

Hypertension

Not recruiting

Study on Lorundrostat for Patients with Uncontrolled and Resistant Hypertension

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lorundrostat
  • Sponsor:Mineralys Therapeutics Inc.

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Neurodermatitis

Not recruiting

Study on the Effects of Povorcitinib for Patients with Prurigo Nodularis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:4-[3-(Cyanomethyl)-3-(3',5'-Dimethyl-1H,1'H-[4,4'-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
  • Sponsor:Incyte Corp.

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in L'aquila

What the registry says about research in the country

01 Dermatological Studies

Current clinical trials focus on innovative treatments for atopic dermatitis and prurigo nodularis, evaluating new therapeutic approaches for managing severe skin conditions.

  • Moderate to severe atopic dermatitis treatment
  • Prurigo nodularis management
  • Alopecia areata interventions

Research emphasizes long-term efficacy and safety of treatments like upadacitinib and amlitelimab.

02 Neurological Research

Studies concentrate on migraine prevention and treatment, including medication overuse headache and innovative approaches using eptinezumab and atogepant.

  • Chronic and episodic migraine management
  • Stroke prevention and treatment
  • Intracerebral hemorrhage interventions

Trials explore both acute treatment options and preventive therapies for neurological conditions.

03 Autoimmune Conditions

Research focuses on treating Sjögren's Syndrome and related autoimmune disorders, evaluating novel therapeutic approaches for systemic manifestations.

  • Systemic disease management
  • Long-term treatment efficacy
  • Symptom control strategies

Studies aim to improve quality of life for patients with chronic autoimmune conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.